Group 1 - The core viewpoint of the news is that 康泰生物 (Kangtai Biological) experienced a decline in stock price and trading volume, with significant changes in financing and shareholder structure [1][2]. Group 2 - On January 27, 康泰生物's stock fell by 3.15%, with a trading volume of 690 million yuan. The financing buy-in amount for the day was 81.14 million yuan, while the financing repayment was 64.88 million yuan, resulting in a net financing buy of 16.26 million yuan. The total financing and securities balance reached 757 million yuan [1]. - As of January 27, the financing balance of 康泰生物 was 750 million yuan, accounting for 4.04% of the circulating market value, which is below the 10% percentile level over the past year, indicating a low position [1]. - The short-selling data on January 27 showed that 康泰生物 had a short-selling repayment of 20,700 shares, with no shares sold short, resulting in a short-selling balance of 688.65 million yuan, which is above the 70% percentile level over the past year, indicating a high position [1]. - As of September 30, 康泰生物 had 63,400 shareholders, an increase of 3.15% from the previous period, with an average of 14,196 circulating shares per person, a decrease of 2.99% [2]. - For the period from January to September 2025, 康泰生物 reported revenue of 2.063 billion yuan, a year-on-year increase of 2.24%, while the net profit attributable to shareholders decreased by 86.00% to 49.16 million yuan [2]. - Since its A-share listing, 康泰生物 has distributed a total of 1.765 billion yuan in dividends, with 525 million yuan distributed over the past three years [2]. - Among the top ten circulating shareholders as of September 30, 易方达创业板ETF (E Fund ChiNext ETF) held 13.2016 million shares, a decrease of 2.2175 million shares from the previous period, while 香港中央结算有限公司 (Hong Kong Central Clearing Limited) increased its holdings by 3.2916 million shares to 7.9866 million shares [2].

每经AI快讯，1月28日，中国证监会国际合作司发布关于上海复宏汉霖生物技术股份有限公司境内未上 市股份"全流通"备案通知书，公司17名股东拟将所持合计182,645,856股境内未上市股份转为境外上市股 份，并在香港联合交易所上市流通。 ...

Core Viewpoint - The company Valiant Biopharma-B (09887) announced that its drug LBL-034 (a GPRC5D/CD3 bispecific antibody) has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed/refractory multiple myeloma (RRMM) [1] Group 1 - The drug LBL-034 is specifically designed to target GPRC5D and CD3, indicating a novel therapeutic approach in the treatment of RRMM [1] - The Fast Track Designation by the FDA is aimed at facilitating the development and expedite the review of drugs that treat serious conditions and fill an unmet medical need [1] - This designation may provide the company with advantages such as more frequent communication with the FDA and eligibility for accelerated approval and priority review [1]

Core Viewpoint - The company Valiant Pharmaceuticals-B (09887) has received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA) for its drug LBL-034 (GPRC5D/CD3 bispecific antibody) aimed at treating relapsed/refractory multiple myeloma (RRMM) [1] Group 1 - The FDA granted Fast Track Designation to LBL-034 on January 27, 2026 [1] - LBL-034 is specifically developed for the treatment of relapsed/refractory multiple myeloma [1]

Group 1 - The core viewpoint of the article highlights the recent stock transfer of Tuo Yun Biotechnology (01332) from Mingji Securities to China Merchants Yonglong Bank, with a market value of HKD 26.8185 million, representing 9.02% of the company [1] - Tuo Yun Biotechnology reported a revenue of HKD 36.581 million for the six months ending June 30, 2025, reflecting a year-on-year decrease of 20.82% [1] - The company achieved a profit attributable to shareholders of HKD 11.243 million, a significant turnaround from a loss of HKD 47.969 million in the same period last year, with earnings per share of HKD 0.004 [1]

Group 1 - The core point of the article highlights the transfer of shares of Tuo Yun Biotechnology (01332) from Mingji Securities to China Merchants Yonglong Bank, with a market value of HKD 26.8185 million, accounting for 9.02% of the total shares [1] - Tuo Yun Biotechnology reported a revenue of HKD 36.581 million for the six months ending June 30, 2025, representing a year-on-year decrease of 20.82% [1] - The company recorded a profit attributable to shareholders of HKD 11.243 million, a significant turnaround from a loss of HKD 47.969 million in the same period last year, with earnings per share of HKD 0.004 [1]

Core Viewpoint - The company Valiant Bio-B (09887.HK) has received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA) for its drug LBL-034, a bispecific antibody targeting GPRC5D/CD3, aimed at treating relapsed/refractory multiple myeloma (RRMM) [1] Group 1 - The FDA granted Fast Track Designation to LBL-034 on January 27, 2026 [1] - LBL-034 is specifically designed for the treatment of relapsed/refractory multiple myeloma [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Nanjing Leads Biolabs Co., Ltd. 南 京 維 立志博生物科技股份有限公司 （於 中 華 人 民 共 和 國 成 立 的 股 份 有 限 公 司） （股 份 代 號：9887） 自願公告 LBL-034（GPRC5D/CD3雙特異性T-CELL ENGAGER，TCE） 獲美國FDA授予快速通道資格認定 本公告由南京 維 立志博生物科技股份有限公司（「本公司」）自 願 作 出，以 告 知 本 公 司 股 東 及 潛 在 投 資 者 有 關 本 公 司 的 最 新 業 務 發 展 情 況。 本 公 司 欣 然 宣 布，於2026年1月27日，LBL-034（GPRC5D/CD3雙 特 異 性 抗 體）獲 美 國食品藥品監督管理局（「FDA」）授予快速通道資格認定（「FTD」），用 於 治 療 復 發╱難 治 性 多 發 性 ...

Core Viewpoint - The major shareholder, Taichang Group, plans to reduce its stake in Chengdu Olin Biotechnology Co., Ltd. due to personal funding needs, with a maximum reduction of 6,000,000 shares, representing up to 1.4789% of the company's total share capital [3][10]. Shareholder Holding Situation - As of the report date, Taichang Group holds 25,893,040 shares, accounting for 6.38% of the total share capital of Olin Biotechnology [2]. Reduction Plan Details - Taichang Group intends to reduce its holdings through centralized bidding or block trading within three months after the announcement, starting 15 trading days post-announcement [3][6]. - The reduction price will be determined based on market conditions at the time of the sale [3]. - If any changes occur in the company's share structure during the reduction period, the planned reduction quantity and ratio will be adjusted accordingly [3]. Commitment and Compliance - Taichang Group has committed not to transfer or manage its pre-IPO shares for 12 months following the company's stock listing [6][7]. - The group will adhere to relevant laws and regulations regarding share reduction, including limits on the number of shares that can be sold within specified periods [7][8]. Historical Context - Taichang Group has not reduced its shareholding since the company went public [5].

Group 1 - The company expects to achieve operating revenue between 1,040 million and 1,080 million yuan for the year 2025, representing an increase of 193.66 million to 233.66 million yuan compared to the previous year, with a year-on-year growth of 22.88% to 27.61% [2] - The company anticipates a net profit attributable to shareholders of the parent company between 24.5 million and 29 million yuan for 2025, indicating a turnaround from a loss in the previous year [2] - The company projects a net profit attributable to shareholders of the parent company, after deducting non-recurring gains and losses, to be between -91 million and -96 million yuan [2] Group 2 - In the previous year, the company reported an operating revenue of 846.34 million yuan, with a total profit of -381.20 million yuan and a net profit attributable to shareholders of the parent company of -378.84 million yuan [4] - The company has focused on innovation and commercialization, leading to sustained revenue growth from its quadrivalent meningococcal vaccine, and has effectively controlled costs, resulting in improved gross margins and overall profitability [4][5] - The company has received significant government subsidies and international funding support due to the rapid advancement of its R&D projects and international collaborations, contributing to substantial non-recurring gains during the reporting period [5]